Adrian Rawcliffe, Adaptimmune CEO at EUBIO22 (Rachel Kiki for Endpoints News)
August 2, 2024 04:08 AM EDTUpdated 04:16 PM
Cell/Gene Tx
FDA+

Adap­ti­m­mune gets FDA ac­cel­er­at­ed ap­proval for T cell re­cep­tor cell ther­a­py in rare soft tis­sue can­cer

Lei Lei Wu

News Reporter

The FDA grant­ed ac­cel­er­at­ed ap­proval to a cell ther­a­py for syn­ovial sar­co­ma, a rare type of can­cer typ­i­cal­ly found in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times